Teicos Pharma is a Finish based Pharmaceutical Start-Up whose business is the production and sales of a new class of inhalable API (active pharmaceutical ingredient) powders for dry powder Inhalers (DPI). According to Mark Lesselroth, the CEO of BioPort “the technology that Dr. David Brown, CEO and Founder of Teicos and his team have developed is truly remarkable. It has the potential to change how patients suffering from diseases that impact the lungs lung including COPD, Asthma and Cystic Fibrosis by providing them more of the drug they need with less side effect” The company has developed a novel dry particle formulation that enable for better absorption of a drug.
Dr. Brown has also invented a unique device for the transmission of this powder formulation. BioPortUSA has been hired to help identify licensing partners in the U.S.A. who see the value in integrating this drug delivery technology with their products.
Teicos Pharma Oy is a leading provider of manufacturing solutions for carrier-free inhalable API powders used in dry powder inhalers.